MISSOURI VALLEY CANCER CONSORTIUM CCOP

密苏里河谷癌症协会 CCOP

• 批准号: 2895126
• 负责人: JAMES A MAILLIARD
• 金额: $ 35.98万
• 依托单位: CANCER ALLIANCE OF NEBRASKA
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-09-30 至 2002-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2895126
• 关键词: behavioral /social science research tag; breast neoplasms; cancer prevention; clinical research; community health services; cooperative study; data management; human subject; human therapy evaluation; neoplasm /cancer education; neoplasm /cancer therapy; patient /disease registry; prostate neoplasms

DESCRIPTION: (Applicant's Description) The Missouri Valley Cancer Consortium (MVCC) is a multi-component community-based cancer research effort based in Omaha and Lincoln, Nebraska. The catchment area includes western Iowa and east-central Nebraska. The 1990 population was about 1.2 million. The MVCC is the third largest accruer of patients to cancer treatment protocols and the second largest to cancer control protocols in the North Central Cancer Treatment Group. The four main components of the MVCC are Alegent Health Bergan Mercy Medical Center, Alegent Health Immanuel Medical Center, Lincoln Cancer Center, and Creighton University. These institutions have had an established research program with the North Central Cancer Treatment Group (NCCTG) since 1983. Numerous investigators (52) participate and are responsible for over 3200 new cancer patients annually. Over the past 2 years of the previous funding period, these investigators have entered 201.1 and 223.4 patients on NCI-approved cancer treatment and control trials, respectively. The proposed principal and associate principal investigators of the MVCC are currently directing the conduct of the Breast Cancer Prevention Trial and the Prostate Cancer Prevention Trial (837 enrolled and 639 randomized for the state of Nebraska. Previous research base affiliations with NCCTG, ECOG, and NSABP would continue with the addition of RTOG and GOG and enable the future support of this high level of accrual as a NCI-funded CCOP.

描述：（申请人的描述）密苏里河谷癌症 联盟 (MVCC) 是一个基于社区的多组成部分癌症研究 总部位于内布拉斯加州奥马哈和林肯。 集水区包括 爱荷华州西部和内布拉斯加州中东部。 1990年人口约为1.2 百万。 MVCC 是癌症治疗患者的第三大受益者 协议和北方第二大癌症控制协议 中央癌症治疗组。 MVCC 的四个主要组件是 Alegent Health Bergan Mercy 医疗中心、Alegent Health Immanuel Medical 中心、林肯癌症中心和克赖顿大学。 这些机构 与中北部癌症中心建立了一项研究计划 治疗组 (NCCTG) 自 1983 年起。众多研究人员 (52) 参与 每年治疗超过 3200 名新癌症患者。 超过 在上一个资助期的过去 2 年里，这些研究人员 纳入 201.1 名和 223.4 名接受 NCI 批准的癌症治疗的患者， 分别进行对照试验。 拟议的校长和助理 MVCC 的主要调查员目前正在指导开展 乳腺癌预防试验和前列腺癌预防试验 （内布拉斯加州 837 人入组，639 人随机分配。上一页 研究基地与 NCCTG、ECOG 和 NSABP 的联系将继续 RTOG 和 GOG 的添加使未来能够支持这种高 NCI 资助的 CCOP 的应计水平。